Related Experiment Video
Updated: Sep 10, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Intrathecal bupivacaine monotherapy in patients with chronic refractory localized pain: a case series
Salim Michel Hayek1,2, Cham Alsalak3
1Division of Pain Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA Salim.Hayek@UHhospitals.org.
Introduction:
Bupivacaine is an established agent in intrathecal drug delivery (IDD), often used in combination with opioids. The efficacy of intrathecal bupivacaine monotherapy has not been reported.
Methods:
A retrospective case series review was undertaken examining patients with chronic pain who underwent device implants and were receiving intrathecal bupivacaine monotherapy. Data collection included patient demographics as well as pain and IDD characteristics.
Results:
Five patients receiving intrathecal bupivacaine monotherapy were identified. All patients had regionally localized pain. Duration of IDD ranged from >2 to >12 years. Two of the patients had initially received a combination of an opioid with bupivacaine but were later transitioned to intrathecal bupivacaine monotherapy. Three of the patients were on systemic opioids prior to IDD. All patients experienced ≥50% pain relief and discontinued systemic opioids.
Conclusion:
IDD with bupivacaine monotherapy may be effective in patients with localized pain. However, more studies are needed to establish the safety and efficacy of intrathecal bupivacaine monotherapy.
Related Concept Videos
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Local Anesthetics: Clinical Application as Spinal Anesthesia
Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia

